3 recruiting, 2 active not recruiting, 2 completed, 1 terminated. 7 Phase 2, 7 Phase 3, 1 Not applicable.
Follow Xiaojun Chen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients GnRHa, Letrozole 2.5mg, Diane-35 - Endometrial Neoplasms, Atypical Endometrial Hyperplasia | Phase 2 / Phase 3 | Recruiting | Xiaojun Chen | 80 | 2022-07-13 | 2026-09-10 |
| GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients GnRH antagonist, Letrozole 2.5mg - Endometrial Neoplasms, Atypical Endometrial Hyperplasia | Phase 2 / Phase 3 | Recruiting | Xiaojun Chen | 29 | 2022-07-13 | 2026-09-10 |
| GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients GnRH antagonist, Letrozole 2.5mg - Atypical Endometrial Hyperplasia, Progesterone Resistance | Phase 2 / Phase 3 | Active not recruiting | Xiaojun Chen | 29 | 2022-07-13 | 2025-08-11 |
| Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet, Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg - Atypical Endometrial Hyperplasia, Fertility Issues | Phase 2 / Phase 3 | Recruiting | Xiaojun Chen | 172 | 2022-06-13 | 2026-06-04 |
| Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet - Endometrial Carcinoma, Obese | Phase 2 / Phase 3 | Terminated | Xiaojun Chen | 8 | 2022-05-01 | 2026-06-04 |
| Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Liraglutide Injection, Megestrol Acetate 160 MG - Atypical Endometrial Hyperplasia, Obese | Phase 2 / Phase 3 | Withdrawn | Xiaojun Chen | 2021-03-20 | 2024-09-26 | |
| Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus sentinel lymph node sampling (SLN), pelvic lymphonodectomy (PLN) - Middle-high Risk Endometrial Cancer, Sentinel Lymph Node Sampling | Not applicable | Active not recruiting | Xiaojun Chen | 780 | 2020-02-13 | 2026-05-12 |
| MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia Medroxyprogesterone Acetate, Dydrogesterone 10 MG - Endometrial Hyperplasia Without Atypia | Phase 3 | Completed | Xiaojun Chen | 471 | 2019-02-26 | 2023-02-17 |
| Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Megestrol acetate and metformin, Megestrol acetate - Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma | Phase 2 | Completed | Xiaojun Chen | 150 | 2013-10-01 | 2021-09-14 |
Endometrial Hyperplasia (6) · Obesity (5) · Endometrial Neoplasms (3) · Infertility (3) · Progesterone Resistance (3) · Overweight (2)
Megestrol Acetate (4) · Letrozole (3) · LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- (2) · Tablets (2) · Cyproterone acetate, ethinyl estradiol drug combination (1) · Dydrogesterone (1) · Levonorgestrel (1) · Liraglutide (1) · Medroxyprogesterone Acetate (1) · Metformin (1)
China (8)